

Synthesis and antiparkinsonian activity of different pyrazolinylpyridinyl indole derivatives

Sunil Kumar^a, Hemlata Kaur^b, K K saxena^b & Yeshowardhana^{*a}

^aDepartment of Chemistry, D.N. (P.G.) College, Meerut, India

^bMedicinal Chemistry Division, Department of Pharmacology, L.L.R.M. Medical College, Meerut 250 004, India

E-mail: drhkaur2012@gmail.com

Accepted 25 September 2014

2-Methyl/ethyl-5-methoxy/ethoxy-3-(2-benzofuran-2-yl)-3-((2-substitutedphenylazo) pyrazolin-4-yl)indoles **3a-l** have been prepared by the reaction of 2-methyl/ethyl-5-methoxy/ethoxy-3-((2-benzofuran-2-yl)-pyrazolin-4-yl)indoles **2a-d** with various substituted benzenediazonium chlorides in presence of sodium acetate. Compounds **3a-l** on reaction with different 4-aminopyridine and formaldehyde yield 2-methyl/ethyl-5-methoxy/ethoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl-3-substitutedphenylazo)-pyrazolin-4-yl)indoles **4a-l**. All the newly synthesized compounds **3a-l** and **4a-l** have been screened for their antiparkinsonian activity. Structures of all the compounds are established by elemental and spectral (IR, ¹H NMR and mass spectroscopic) analysis.

Keywords: Indoles, pyrazolinylindoles, pyrazolinylpyridinylindoles, antiparkinsonian activity, acute toxicity

Parkinson's disease is a terminal late onset neurodegenerative disorder characterized by a progressive and relatively selective degeneration of dopaminergic neurons in the substantia nigra¹. Indole derivatives have been reported to possess different biological and pharmacological activities like anti-parkinsonian²⁻⁴, anticonvulsant⁵, anti-inflammatory⁶ and antipsychotic⁷. Furthermore, various derivatives of benzofuran and pyrazoline have been reported to exhibit antiparkinsonian activity^{8,9}. Moreover, different derivatives of pyridine have been shown to possess wide range of biological properties including antiparkinsonian¹⁰⁻¹² and anticonvulsant activity¹³. In the light of above discussion, various derivatives of indole have been synthesized by incorporating benzofuran, pyrazoline and pyridine moieties with the hope to get better antiparkinsonian agents.

Results and Discussion


Synthetic routes of indole derivatives are outlined in **Scheme I**. 2-Acetylbenzofuran was reacted with different substituted indole-3-aldehydes to give 2-methyl/ethyl-5-methoxy / ethoxy-3-(2-benzofuran-2-yl-chalconyl)indoles **1a-d**, which on cyclization with hydrazine hydrate in presence of glacial acetic acid yielded 2-Methyl/ethyl-5-methoxy/ethoxy-3-((2-benzofuran-2-yl)-pyrazolin-4-yl)indoles **2a-d**. Compounds **2a-d** on reaction with different substituted benzene

diazoniumchlorides afforded 2-methyl/ethyl-5-methoxy/ethoxy-3-(2-benzofuran-2-yl)- 3-(2-substituted-phenylazo) pyrazolin-4-yl)indoles **3a-l** which on Mannich reaction with 4-aminopyridine and formaldehyde gave 2-methyl/ethyl-5-methoxy/ethoxy-3-((2-benzofuran-2-yl)- 1-(pyridinylamino)methyl-3-substitutedphenyl-azo)-pyrazolin-4-yl) indoles **4a-l**. The homogeneity of all synthesized compounds was determined by thin layer chromatography using several solvent systems of different polarity.

Material and Methods

Antiparkinsonian activity: All the newly synthesized compounds have been evaluated for their antiparkinsonian activity. The study was carried out on albino rats weighing 100-200 g and mice 20-30 g of either sex. The animals were provided feed and allowed water *ad libidum*. The number of animals in each group was 5. All the compounds were administered in a dose of 100 mg/kg i.p.

Tremors: This activity was conducted by the method of D M Coward and M S Dogges¹⁴. Tremors were induced by oxotremorine (OT) (0.5 mg/kg i.p) in mice 45 min after pretreatment with the test compounds. After 5 min of OT injection, tremors were assessed visually and scored as: 0 = no tremor; 1 = occasional tremor; 2 = intermittent tremors;



Scheme I

3 = continuous tremors. Each animal of a group was scored and tremor index (mean score for each group) determined.

Rigidity: Reserpine (5 mg/kg i.p.) was administered in rats to produce rigidity and after 15 min, test compounds were injected. Rigidity was measured 1 hr after reserpine administration. To measure rigidity, rats were grasped immediately below forelimbs and slight pressure was applied upward against the hind limbs. The degree of resistance was scored according to Goldstein *et al.*¹⁵: 0 = no resistance; 1 = normal resistance; 2 = complete resistance. A score of 2 was selected as criterion for rigidity and expressed as percentage of animals showing rigidity (score 2) in a group.

Hypokinesia: This was performed according to the method of Morpugo¹⁶. It was produced by reserpine (5 mg/kg i.p.) in rats. Locomotor activity was measured after 2 hr by placing each group of rats in a photoactometer for 15 min and total counts were recorded. The test compounds were administered 15 min after reserpine administration. The percent increase of decrease in counts was calculated on the basis of counts of untreated groups.

Acute toxicity study: The compounds which showed significant antiparkinsonian activity were investigated for their acute toxicity study in mice (25-30g) of their sex. The compounds were given orally at graded doses to separated groups of animals. After 24 hr of administration, percent mortality in each group was observed from the data obtained. LD₅₀ values were calculated by the method of Smith¹⁷.

Experimental Section

All reagents and solvents used in the study were of analytical grade and procured locally. The progress of the reaction was monitored by TLC and the products were purified by recrystallization and homogeneity of the compounds was checked by thin layer chromatography (TLC) performed on silica gel G coated plate of 0.5 mm thickness. The elemental analysis, spectral studies, IR, and ¹H NMR were determined by standard methods. Infrared (IR) spectra were recorded in KBr on Perkin-Elmer-spectrum RX-I instrument and ν_{max} was recorded in cm^{-1} . The ¹H NMR spectra were recorded in CDCl₃ and DMSO-*d*₆ on Bruker DRX-300 FTNMR instrument. ¹³C NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer using solvent peak as internal standard. Mass spectra were determined on VG-70-S instrument.

General procedure for preparation of 2-methyl/ethyl-5-methoxy/ethoxy-3-(2-benzofuran-2-yl-chalconyl)-indoles, 1a-d.

A solution of 2-methyl/ethyl-5-methoxy/ethoxyindol-3-aldehyde (1.5 mol) in absolute methanol (100 mL) in 2% NaOH and 2-acetylbenzofuran (1.5 mol) was refluxed for 10 hr, concentrated, cooled and poured onto ice. The solid thus obtained was filtered, washed with water and purified by recrystallization from appropriate solvent to obtain compounds **1a-d**.

2-Methyl-5-methoxy-3-(2-benzofuran-2-yl-chalconyl)indole, 1a: Yield 75% (Methanol); m.p. 132°C. IR (KBr): 1035 (C-O-C), 1615 (C=C of aromatic ring), 1715 (C=O, COCH), 3352 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.38 (s, 3H, CH₃), 3.40 (s, 3H, OCH₃), 5.60 (d, 1H, *J* = 9.0 Hz, COCH=CH), 6.70 (d, 1H, *J* = 9.1 Hz, COCH=CHAr), 6.85-7.89 (m, 8H, Ar-H), 8.72 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 15.9, 55.8, 104.8, 111.5, 112.1, 112.2, 105.9, 116.6, 120.9, 123.3, 124.7, 127.2, 127.3, 127.5, 127.8, 131.1, 145.1, 154.0, 155.2, 160.5, 177.8; MS: [M]⁺ at *m/z* 331.36. Anal. Calcd for C₂₁H₁₇NO₃: C, 76.12; H, 5.17; N, 4.23. Found: C, 76.11; H, 5.19; N, 4.25%.

2-Methyl-5-ethoxy-3-(2-benzofuran-2-yl-chalconyl)indole, 1b: Yield 71% (Methanol); m.p. 138°C. IR (KBr): 1038 (C-O-C), 1618 (C=C of aromatic ring), 1714 (C=O, COCH), 3355 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.38 (s, 3H, CH₃), 2.36 (t, 3H, *J* = 7.1 Hz OCH₂CH₃), 3.90 (q, 2H, *J* = 7.3 Hz, OCH₂CH₃), 5.63 (d, 1H, *J* = 9.0 Hz, COCH=CH), 6.72 (d, 1H, *J* = 9.1 Hz, COCH=CHAr), 6.88-7.87 (m, 8H, Ar-H), 8.70 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 14.8, 15.9, 64.6, 104.9, 105.9, 153.4, 111.5, 111.7, 116.6, 117.1, 117.8, 120.9, 123.3, 124.7, 126.8, 127.3, 127.8, 131.1, 145.1, 155.2, 160.5; MS: [M]⁺ at *m/z* 345.39. Anal. Calcd for C₂₂H₁₉NO₃: C, 76.50; H, 5.54; N, 4.06. Found: C, 76.52; H, 5.52; N, 4.09%.

2-Ethyl-5-methoxy-3-(2-benzofuran-2-yl-chalconyl)indole, 1c: Yield 72% (Ethanol); m.p. 133°C. IR (KBr): 1039 (C-O-C), 1613 (C=C of aromatic ring), 1718 (C=O, COCH), 3357 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.32 (t, 3H, *J* = 7.0 Hz, CH₂CH₃), 2.82 (q, 2H, *J* = 7.1 Hz, CH₂CH₃), 3.46 (s, 3H, OCH₃), 5.63 (d, 1H, *J* = 9.0 Hz, COCH=CH), 6.72 (d, 1H, *J* = 9.1 Hz, COCH=CHAr), 6.78-7.87 (m, 8H, Ar-H), 8.71 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 14.1, 22.4, 55.8, 104.8, 105.9, 111.5, 112.1, 112.2, 116.6, 120.9, 123.3, 124.7, 127.2, 127.3, 127.5,

127.8, 137, 145.1, 154.0, 155.2, 160.5, 177.8; MS: [M]⁺ at *m/z* 345.39. Anal. Calcd. for C₂₂H₁₉NO₃: C, 76.50; H, 5.54; N, 4.06. Found: C, 76.54; H, 5.53; N, 4.10%.

2-Ethyl-5-ethoxy-3-(2-benzofuran-2-yl-chalconyl)indole, 1d: Yield 71% (Methanol); m.p. 140°C. IR (KBr): 1040 (C-O-C), 1614 (C=C of aromatic ring), 1715 (C=O, COCH) 3356 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.27 (t, 3H, *J* = 7.0 Hz, CH₂CH₃), 2.35 (t, 3H, *J* = 7.2 Hz OCH₂CH₃), 3.84 (q, 2H, *J* = 7.3 Hz, CH₂CH₃), 3.86 (q, 2H, *J* = 7.3 Hz, OCH₂CH₃), 5.63 (d, 1H, *J* = 9.0 Hz, COCH=CH), 6.72 (d, 1H, *J* = 9.1 Hz, COCH=CHAr), 6.98-7.89 (m, 8H, Ar-H), 8.78 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 14.1, 14.8, 22.4, 104.9, 105.9, 111.5, 111.7, 115.5, 116.6, 117.1, 120.9, 123.3, 124.7, 126.8, 127.3, 127.8, 137, 145.1, 153.4, 155.2, 160.5, 177.8; MS: [M]⁺ at *m/z* 359.42. Anal. Calcd for C₂₃H₂₁NO₃: C, 76.86; H, 5.89; N, 3.90. Found: C, 76.84; H, 5.93; N, 3.92%.

General procedure for preparation of 2-methyl/ethyl-5-methoxy/ethoxy-3-(2-benzofuran-2-yl)-pyrazolin-4-yl)indoles, 2a-d.

To a solution of **1a-d** (0.4 mol) in methanol, hydrazine hydrate (99%) (0.4 mol) and a few drops of glacial acetic acid were added. The reaction mixture was refluxed for 8-10 hr, the solvent distilled out the reaction mass cooled. The separated solid was filtered, washed with water and purified by recrystallization from suitable solvent to furnish compounds **2a-d**.

2-Methyl-5-methoxy-3-((2-benzofuran-2-yl)-pyrazolin-4-yl)indole, 2a: Yield 70% (Methanol); m.p. 145°C. IR (KBr): 1042 (C-O-C), 1294 (N-N of pyrazoline ring), 1584 (C=N), 1616 (C=C of aromatic ring), 1710 (C=O, COCH₃), 3358 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.32 (s, 3H, CH₃), 3.42 (s, 3H, OCH₃), 3.61 (s, 3H, N-COCH₃), 3.75 (d, 2H, *J* = 9.0 Hz, CH₂ of pyrazoline ring), 5.75 (t, 1H, *J* = 9.35 Hz, CH of pyrazoline ring), 6.85-7.89 (m, 8H, Ar-H), 8.72 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 15.9, 23.4, 42.4, 51.4, 55.8, 103, 104.8, 111.5, 112.1, 112.2, 115.6, 119.2, 123.3, 124.7, 127.2, 127.5, 129.8, 131.1, 141.4, 151.7, 154.0, 155.1, 168.5; MS: [M]⁺ at *m/z* 387.43. Anal. Calcd for C₂₃H₂₁N₃O₃: C, 71.30; H, 5.46; N, 10.85. Found: C, 71.28; H, 5.44; N, 10.84%.

2-Methyl-5-ethoxy-3-((2-benzofuran-2-yl)-pyrazolin-4-yl)indole, 2b: Yield 68% (Acetone); m.p. 149°C. IR (KBr): 1046 (C-O-C), 1290 (N-N of

pyrazoline ring), 1583 (C=N), 1612 (C=C of aromatic ring), 1714 (C=O, COCH₃), 3356 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.42 (s, 3H, CH₃), 2.36 (t, 3H, *J* = 7.3 Hz OCH₂CH₃), 2.87 (q, 2H, *J* = 7.2 Hz, OCH₂CH₃), 3.65 (s, 3H, N-COCH₃), 3.75 (d, 2H, *J* = 9.0 Hz, CH₂ of pyrazoline ring), 5.75 (t, 1H, *J* = 9.30 Hz, CH of pyrazoline ring), 6.88-7.87 (m, 8H, Ar-H), 8.70 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 14.8, 15.9, 23.4, 42.4, 51.4, 64.6, 103, 104.9, 111.5, 111.7, 115.6, 117.1, 119.2, 123.3, 124.7, 126.8, 129.8, 131.1, 137, 141.4, 151.7, 153.4, 155.1, 168.5; MS: [M]⁺ at *m/z* 401.46. Anal. Calcd for C₂₄H₂₃N₃O₃: C, 71.80; H, 5.77; N, 10.47; Found: C, 71.79; H, 5.75; N, 10.45%.

2-Ethyl-5-methoxy-3-((2-benzofuran-2-yl)-pyrazolin-4-yl)indole, 2c: Yield 72% (Petroleum ether); m.p. 141°C. IR (KBr): 1041 (C-O-C), 1292 (N-N of pyrazoline ring), : 1584 (C=N), 1615 (C=C of aromatic ring), 1711 (C=O, COCH₃), 3356 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.34 (t, 3H, *J* = 7.1 Hz, CH₂CH₃), 2.78 (q, 2H, *J* = 7.2 Hz, CH₂CH₃), 3.46 (s, 3H, OCH₃), 3.62 (s, 3H, N-COCH₃), 3.75 (d, 2H, *J* = 9.0 Hz, CH₂ of pyrazoline ring), 5.75 (t, 1H, *J* = 9.35 Hz, CH of pyrazoline ring), 6.88-7.87 (m, 8H, Ar-H), 8.72 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 22.4, 23.4, 42.4, 51.4, 55.8, 103, 104.8, 111.5, 112.1, 112.2, 115.6, 119.2, 123.3, 124.7, 127.2, 127.5, 129.8, 137, 141.4, 151.7, 154.0, 155.1, 168.5; MS: [M]⁺ at *m/z* 401.46. Anal. Calcd for C₂₄H₂₃N₃O₃: C, 71.80; H, 5.77; N, 10.47. Found: C, 71.81; H, 5.78; N, 10.46%.

2-Ethyl-5-ethoxy-3-((2-benzofuran-2-yl)-pyrazolin-4-yl)indole, 2d: Yield 67% (Methanol); m.p. 146°C. IR (KBr): 1044 (C-O-C), 1290 (N-N of pyrazoline ring), 1586 (C=N), 1617 (C=C of aromatic ring), 1714 (C=O, COCH₃), 3353 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.30 (t, 3H, *J* = 7.0 Hz, CH₂CH₃), 2.38 (t, 3H, *J* = 7.3 Hz OCH₂CH₃), 2.78 (q, 2H, *J* = 7.0 Hz, CH₂CH₃), 3.52 (q, 2H, *J* = 7.3 Hz, OCH₂CH₃), 3.68 (s, 3H, N-COCH₃), 3.75 (d, 2H, *J* = 9.0 Hz, CH₂ of pyrazoline ring), 5.75 (t, 1H, *J* = 9.31 Hz, CH of pyrazoline ring), 6.88-7.87 (m, 8H, Ar-H), 8.72 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 11.7, 13.7, 14.8, 22.4, 23.4, 42.4, 51.4, 64.6, 103, 104.9, 111.5, 115.6, 117.1, 119.2, 123.3, 124.7, 126.8, 129.8, 137, 151.7, 153.4, 141.4, 151.4, 155.1, 168.5; MS: [M]⁺ at *m/z* 405.21. Anal. Calcd for C₂₅H₂₅N₃O₃: C, 72.27; H, 6.06; N, 10.11. Found: C, 71.25; H, 6.08; N, 10.13 %.

General procedure for preparation of 2-methyl/ethyl-5-methoxy/ethoxy-3-((2-benzofuran-2-yl)-3-(2-substituted phenylazo) pyrazolin-4-yl) indoles, 3a-l.

Aryldiazonium salt solution of different anilines (0.1 mol) was added drop wise with stirring to the ethanolic solution of compounds **2a-d** (0.1 mol) containing sodium acetate (0.1 mol) at 0-5°C. The reaction mixture was kept at RT for 2 hr and poured onto ice cold water. The solid thus obtained was washed several times with water filtered and then purified by recrystallization from suitable solvents to afford compounds **3a-l**.

2-Methyl-5-methoxy-3-((2-benzofuran-2-yl)-3-(phenylazo)pyrazolin-4-yl)indole 3a: Yield 65% (Ethanol); m.p. 172°C. IR (KBr): 1050 (C-O-C), 1292 (N-N of pyrazoline ring), 1421 (N=N), 1584 (C=N), 1613 (C=C of aromatic ring), 1716 (C=O, COCH₃), 3354 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.34 (s, 3H, CH₃), 3.48 (s, 3H, OCH₃), 3.74 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 3.85 (s, 3H, N-COCH₃), 5.77 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.78-7.99 (m, 13H, Ar-H), 8.82 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 15.9, 23.4, 38.6, 55.8, 70.4, 103, 104.8, 112.1, 112.1, 111.5, 115.6, 119.2, 122.6, 123.3, 124.7, 125.7, 127.2, 127.5, 129.2, 129.8, 131.1, 141.4, 150.9, 154.0, 155.1, 155.6, 168.5; MS: [M]⁺ at *m/z* 491.54. Anal. Calcd for C₂₉H₂₅N₅O₃: C, 70.86; H, 5.13; N, 14.25. Found: C, 70.88; H, 5.12; N, 14.24%.

2-Methyl-5-methoxy-3-((2-benzofuran-2-yl)-3-(2-chlorophenylazo)pyrazolin-4-yl) indole, 3b: Yield 74% (Acetone); m.p. 168°C. IR (KBr): 750 (C-Cl), 1058 (C-O-C), 1294 (N-N of pyrazoline ring), 1425 (N=N), 1587 (C=N), 1617 (C=C of aromatic ring), 1718 (C=O, COCH₃), 3357 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.38 (s, 3H, CH₃), 3.53 (s, 3H, OCH₃), 3.71 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 3.86 (s, 3H, N-COCH₃), 5.72 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.85-7.79 (m, 12H, Ar-H), 8.89 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 15.9, 23.4, 38.6, 55.8, 70.4, 103, 104.8, 111.5, 112.1, 112.2, 115.6, 119.2, 123.3, 124.0, 124.7, 127.1, 127.2, 127.3, 127.5, 128.1, 129.3, 129.8, 131.1, 141.4, 151.1, 154.0, 155.1, 155.6, 168.5; MS: [M]⁺ at *m/z* 525.99. Anal. Calcd for C₂₉H₂₄ClN₅O₃: C, 66.22; H, 4.60; N, 13.31. Found: C, 66.24; H, 4.58; N, 13.32%.

2-Methyl-5-methoxy-3-((2-benzofuran-2-yl)-3-(2-methoxyphenylazo)pyrazolin-4-yl)indole, 3c: Yield 70% (Methanol); m.p. 178°C. IR (KBr): 1056 (C-O-C), 1292 (N-N of pyrazoline ring), 1422 (N=N),

1588 (C=N), 1619 (C=C of aromatic ring), 1715 (C=O, COCH₃), 3352 cm⁻¹ (NH). ¹H NMR (CDCl₃): δ 1.40 (s, 3H, CH₃), 3.56 (s, 6H, 2 × OCH₃), 3.76 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 3.80 (s, 3H, N-COCH₃), 5.70 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.87-7.89 (m, 12H, Ar-H), 8.93 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 15.9, 23.4, 38.6, 55.8, 70.4, 103, 104.8, 112.1, 112.2, 114.8, 115.6, 119.2, 121.5, 121.7, 122.8, 123.3, 123.6, 124.7, 127.2, 127.5, 129.8, 131.1, 141.4, 152.8, 154.0, 155.1, 155.6, 168.5; MS: [M]⁺ at *m/z* 521.57. Anal. Calcd for C₃₀H₂₇N₅O₄: C, 69.08; H, 5.22; N, 13.43. Found: C, 69.09; H, 5.20; N, 13.45%.

2-Methyl-5-ethoxy-3-((2-benzofuran-2-yl)-3-(phenylazo)pyrazolin-4-yl)indole, 3d: Yield 77% (Methanol); m.p. 170°C. IR (KBr): 1058 (C-O-C), 1295 (N-N), 1426 (N=N), 1589 (C=N), 1620 (C=C of aromatic ring), 1717 (C=O, COCH₃), 3358 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.30 (s, 3H, CH₃), 1.92 (t, 3H, *J* = 7.0 Hz, OCH₂CH₃), 3.84 (q, 2H, *J* = 7.1 Hz, OCH₂CH₃), 3.76 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 3.81 (s, 3H, N-COCH₃), 5.69 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.87-7.78 (m, 13H, Ar-H), 8.95 (s, 1H, indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 14.8, 15.9, 23.4, 38.6, 55.8, 64.6, 70.4, 103, 104.9, 111.5, 111.7, 114.8, 115.6, 117.1, 119.2, 121.5, 121.7, 122.8, 123.3, 123.6, 124.7, 126.8, 129.8, 126.8, 131.1, 141.4, 152.8, 153.4, 155.1, 155.6, 168.5; MS: [M]⁺ at *m/z* 505.57. Anal. Calcd for C₃₀H₂₇N₅O₃: C, 71.27; H, 5.38; N, 13.85. Found: C, 71.28; H, 5.39; N, 13.82%.

2-Methyl-5-ethoxy-3-((2-benzofuran-2-yl)-3-(2-chlorophenylazo)pyrazolin-4-yl)indole, 3e: Yield 69% (Ethanol); m.p. 187°C. IR (KBr): 756 (C-Cl), 1056 (C-O-C), 1292 (N-N), 1422 (N=N), 1590 (C=N), 1625 (C=C of aromatic ring), 1722 (C=O, COCH₃), 3352 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.35 (s, 3H, CH₃), 1.88 (t, 3H, *J* = 7.0 Hz, OCH₂CH₃), 3.89 (q, 2H, *J* = 7.3 Hz, OCH₂CH₃), 3.79 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 3.81 (s, 3H, N-COCH₃), 5.67 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.77-7.88 (m, 12H, Ar-H), 8.98 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 14.8, 15.9, 22.8, 46.6, 64.6, 67.5, 102.0, 103, 104.9, 111.7, 117.1, 126.8, 111.5, 120.9, 123.3, 124.0, 124.7, 126.8, 126.9, 127.1, 127.3, 128.1, 129.3, 131.1, 151.1, 153.4, 154.1, 155.6, 159.6, 168.5; MS: [M]⁺ at *m/z* 540.01. Anal. Calcd for C₃₀H₂₆ClN₅O₃: C, 66.72; H, 4.85; N, 12.97. Found: C, 66.70; H, 4.86; N, 12.96%.

2-Methyl-5-ethoxy-3-((2-benzofuran-2-yl)-3-(2-methoxyphenylazo)pyrazolin-4-yl)indole, 3f: Yield 71% (Methanol); m.p. 190°C. IR (KBr): 1056 (C-O-C), 1293 (N-N), 1425 (N=N), 1593 (C=N), 1623 (C=C of aromatic ring), 1727 (C=O, COCH₃), 3356 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.29 (s, 3H, CH₃), 2.34 (t, 3H, *J* = 7.0 Hz, OCH₂CH₃), 2.92 (q, 2H, *J* = 7.2 Hz, OCH₂CH₃), 3.55 (s, 3H, OCH₃), 3.70 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 3.75 (s, 3H, N-COCH₃), 5.69 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.97-7.79 (m, 12H, Ar-H), 8.92 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 14.8, 15.9, 22.8, 46.6, 55.8, 64.6, 67.5, 102.0, 103, 104.9, 111.5, 111.7, 114.8, 117.1, 120.9, 121.5, 121.1, 122.8, 123.3, 123.6, 126.8, 126.9, 131.1, 152.8, 153.4, 154.1, 155.6, 159.6, 168.5; MS: [M]⁺ at *m/z* 535.59. Anal. Calcd for C₃₁H₂₉N₅O₄: C, 69.52; H, 5.46; N, 13.08. Found: C, 69.50; H, 5.47; N, 13.06%.

2-Ethyl-5-methoxy-3-((2-benzofuran-2-yl)-3-(phenylazo)pyrazolin-4-yl)indole, 3g: Yield 72% (Petroleum ether); m.p. 183°C. IR (KBr): 1049 (C-O-C), 1295 (N-N), 1426 (N=N), 1585 (C=N), 1622 (C=C of aromatic ring), 1720 (C=O, COCH₃), 3349 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.37 (t, 3H, *J* = 7.0 Hz, CH₂CH₃), 2.74 (q, 2H, *J* = 7.2 Hz, CH₂CH₃), 3.59 (s, 3H, OCH₃), 3.74 (d, 1H, *J* = 7.4 Hz, CH of pyrazoline ring), 3.80 (s, 3H, N-COCH₃), 5.69 (d, 1H, *J* = 7.4 Hz, CH of pyrazoline ring), 6.97-7.79 (m, 13H, Ar-H), 8.98 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 22.4, 22.8, 46.4, 55.8, 67.5, 102.0, 103, 104.8, 111.5, 112.1, 112.2, 120.9, 122.6, 123.3, 124.7, 125.7, 126.9, 127.2, 127.5, 129.2, 137, 150.9, 154.0, 154.1, 155.6, 159.6, 168.5; MS: [M]⁺ at *m/z* 505.57. Anal. Calcd for C₃₀H₂₇N₅O₃: C, 71.27; H, 5.38; N, 13.85. Found: C, 71.26; H, 5.39; N, 13.84%.

2-Ethyl-5-methoxy-3-((2-benzofuran-2-yl)-3-(2-chlorophenylazo)pyrazolin-4-yl)indole, 3h: Yield 75% (Petroleum ether); m.p. 194°C. IR (KBr): 752 (C-Cl), 1053 (C-O-C), 1290 (N-N), 1424 (N=N), 1629 (C=C of aromatic ring), 1593 (C=N), 1718 (C=O, COCH₃), 3357 cm⁻¹ (NH). ¹H NMR (CDCl₃): δ MS: 2.34 (t, 3H, *J* = 7.0 Hz, CH₂CH₃), 2.85 (q, 2H, *J* = 7.2 Hz, CH₂CH₃), 3.53 (s, 3H, OCH₃), 3.72 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 3.75 (s, 3H, N-COCH₃), 5.62 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.87-7.89 (m, 12H, Ar-H), 8.91 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 22.4, 22.8, 46.6, 55.8, 67.5, 102.0, 103, 104.8, 111.5, 112.1, 112.2, 120.9, 123.3, 124.0, 124.7, 126.9, 127.1, 127.3, 127.5, 128.1, 129.3, 137, 154.1, 155.6, 159.6, 127.2,

154.0, 168.5; $[M]^+$ at m/z 540.01. Anal. Calcd for $C_{30}H_{26}ClN_5O_3$: C, 66.72; H, 4.85; N, 12.97. Found: C, 66.71; H, 4.86; N, 12.95%

2-Ethyl-5-methoxy-3-((2-benzofuran-2-yl)-3-(2-methoxyphenylazo)pyrazolin-4-yl)indole, 3i: Yield 74% (Methanol); m.p. 199°C. IR (KBr): 1056 (C-O-C), 1294 (N-N), 1424 (N=N), 1594 (C=N), 1624 (C=C of aromatic ring), 1721 (C=O, COCH₃), 3351 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.37 (t, 3H, $J = 7.0$ Hz, CH₂CH₃), 2.81 (q, 2H, $J = 7.2$ Hz, CH₂CH₃), 3.59 (s, 6H, 2 × OCH₃), 3.74 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 3.87 (s, 3H, N-COCH₃), 5.69 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 6.97-7.69 (m, 12H, Ar-H), 8.93 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 22.4, 22.8, 46.6, 55.8, 67.5, 102.0, 103, 104.8, 111.5, 112.1, 112.2, 114.8, 120.9, 121.5, 121.7, 122.8, 123.3, 123.6, 124.7, 126.9, 127.2, 127.5, 137, 152.8, 154.0, 154.1, 155.6, 159.6, 168.5; MS: $[M]^+$ at m/z 535.59. Anal. Calcd for $C_{31}H_{29}N_5O_4$: C, 69.52; H, 5.46; N, 13.08. Found: C, 69.50; H, 5.47; N, 13.06%.

2-Ethyl-5-ethoxy-3-((2-benzofuran-2-yl)-3-(phenylazo)pyrazolin-4-yl)indole, 3j: Yield 70% (Ethanol); m.p. 175°C. IR (KBr): 1062 (C-O-C), 1292 (N-N), 1422 (N=N), 1590 (C=N), 1625 (C=C of aromatic ring), 1722 (C=O, COCH₃), 3357 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.30 (t, 3H, $J = 7.0$ Hz, CH₂CH₃), 2.33 (t, 3H, OCH₂CH₃), 2.90 (q, 2H, $J = 7.2$ Hz, CH₂CH₃), 3.54 (q, 2H, $J = 7.3$ Hz, OCH₂CH₃), 3.78 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 3.82 (s, 3H, N-COCH₃), 5.66 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 6.69-7.69 (m, 13H, Ar-H), 8.90 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 14.8, 22.4, 22.8, 46.6, 64.6, 67.5, 102.0, 103, 104.9, 111.5, 111.7, 117.1, 120.9, 122.6, 123.3, 124.7, 125.7, 126.8, 126.9, 129.2, 137, 150.9, 153.4, 154.1, 155.6, 159.6, 168.5; MS: $[M]^+$ at m/z 519.59. Anal. Calcd for $C_{31}H_{29}N_5O_3$: C, 71.66; H, 5.63; N, 13.48. Found: C, 71.65; H, 5.64; N, 13.47%.

2-Ethyl-5-ethoxy-3-((2-benzofuran-2-yl)-3-(2-chlorophenylazo)pyrazolin-4-yl)indole, 3k: Yield 70% (Methanol); m.p. 186°C. IR (KBr): 753 (C-Cl), 1054 (C-O-C), 1294 (N-N), 1425 (N=N), 1595 (C=N), 1630 (C=C of aromatic ring), 1730 (C=O, COCH₃), 3354 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.29 (t, 3H, $J = 7.0$ Hz, CH₂CH₃), 2.37 (t, 3H, $J = 7.1$ Hz, OCH₂CH₃), 2.94 (q, 2H, $J = 7.2$ Hz, CH₂CH₃), 3.54 (q, 2H, $J = 7.3$ Hz, OCH₂CH₃), 3.78 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 3.83 (s, 3H, N-COCH₃), 5.64 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 6.66-7.66

(m, 12H, Ar-H), 8.89 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 14.8, 22.4, 22.8, 46.6, 64.6, 67.5, 102.0, 103, 104.9, 111.5, 111.7, 117.1, 120.9, 123.3, 124.0, 124.7, 126.8, 126.9, 127.1, 127.3, 128.1, 129.3, 137, 151.1, 153.4, 154.1, 155.6, 159.6, 168.5; MS: $[M]^+$ at m/z 554.04. Anal. Calcd for $C_{31}H_{28}ClN_5O_3$: C, 67.20; H, 5.09; N, 12.64. Found: C, 67.21; H, 5.10; N, 12.66%.

2-Ethyl-5-ethoxy-3-((2-benzofuran-2-yl)-3-(2-methoxyphenylazo)pyrazolin-4-yl)indole, 3l: Yield 71% (Methanol); m.p. 197°C. IR (KBr): 1057 (C-O-C), 1294 (N-N), 1423 (N=N), 1593 (C=N), 1623 (C=C of aromatic ring), 1725 (C=O, COCH₃), 3352 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.32 (t, 3H, $J = 7.0$ Hz, CH₂CH₃), 2.41 (t, 3H, $J = 7.3$ Hz, OCH₂CH₃), 2.90 (q, 2H, $J = 7.2$ Hz, CH₂CH₃), 3.60 (q, 2H, $J = 7.3$ Hz, OCH₂CH₃), 3.72 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 3.75 (s, 3H, N-COCH₃), 3.55 (s, 3H, OCH₃), 5.62 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 6.79-7.99 (m, 12H, Ar-H), 8.90 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 14.8, 22.4, 22.8, 46.6, 55.8, 64.6, 67.5, 102.0, 103, 104.9, 111.5, 111.7, 114.8, 117.1, 120.9, 121.5, 121.7, 121.8, 122.8, 123.3, 123.6, 124.7, 126.8, 126.9, 137, 152.8, 153.4, 154.1, 155.6, 159.6, 168.5; MS: $[M]^+$ at m/z 549.24. Anal. Calcd for $C_{32}H_{31}N_5O_4$: C, 69.93; H, 5.69; N, 12.74. Found: C, 69.95; H, 5.67; N, 12.76%.

General procedure for preparation of 2-methyl/ethyl-5-methoxy/ethoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl-3-substitutedphenylazo)-pyrazolin-4-yl)indoles, 4a-l.

To the solution of compound **3a-l** (0.03 mol) in methanol, formaldehyde (0.06 mol) and different anilines (0.02 mol) were added and refluxed for 4-6 hr. The resultant mixture was concentrated, cooled and poured onto ice. Separated solid was filtered and purified by recrystallization from suitable solvents to yielded compounds **4a-l**.

2-Methyl-5-methoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl-3-(phenylazo)pyrazolin-4-yl)indole, 4a: Yield 60% (Ethanol); m.p. 242°C. IR (KBr): 1039 (C-O-C), 1292 (N-N), 1422 (N=N), 1590 (C=N), 1625 (C=C of aromatic ring), 1722 (C=O, COCH₃), 3355 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.45 (s, 3H, CH₃), 3.12 (t, 2H, $J = 6.0$ Hz, CH₂CH₂), 3.16 (q, 2H, $J = 7.2$ Hz, CH₂NH), 3.54 (s, 3H, OCH₃), 3.74 (d, 1H, $J = 7.4$ Hz, CH of pyrazoline ring), 5.40 (brs, 1H, NHCH₂ exchangeable with D₂O), 5.77 (d, 1H, $J = 7.4$ Hz, CH of pyrazoline ring), 6.78-7.99 (m, 17H,

Ar-H), 8.82 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 15.9, 34.7, 39.0, 46.9, 55.8, 67.5, 102.0, 103, 104.8, 107.3, 111.5, 112.1, 112.2, 120.9, 122.6, 123.3, 124.7, 125.7, 127.2, 127.5, 129.2, 129.6, 126.9, 131.1, 154.0, 150.2, 150.9, 154.1, 154.9, 155.6, 159.6, 171.7. MS: [M]⁺ at *m/z* 597.67. Anal. Calcd for C₃₅H₃₁N₇O₃: C, 70.34; H, 5.23; N, 16.40; Found: C, 69.35; H, 5.22; N, 16.42%.

2-Methyl-5-methoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl)-3-(2-chlorophenylazo) pyrazolin-4-yl)indole, 4b: Yield 70% (Acetone); m.p. 232°C. IR (KBr): 756 (C-Cl), 1044 (C-O-C), 1291 (N-N), 1426 (N=N), 1589 (C=N), 1625 (C=C of aromatic ring), 1730 (C=O), 3346 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.49 (s, 3H, CH₃), 3.15 (t, 2H, *J* = 6.0 Hz, CH₂CH₂), 3.20 (q, 2H, *J* = 7.2 Hz, CH₂NH), 3.53 (s, 3H, OCH₃), 3.71 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 5.48 (brs, 1H, NHCH₂ exchangeable with D₂O), 5.72 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.85-7.79 (m, 16H, Ar-H), 8.89 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 15.9, 34.7, 39.0, 46.9, 55.8, 67.5, 102.0, 102.9, 103, 104.8, 107.3, 112.1, 112.2, 111.5, 123.3, 124.0, 124.7, 126.9, 127.1, 127.2, 127.3, 127.5, 128.1, 129.3, 131.1, 150.2, 151.1, 154.0, 154.1, 154.9, 159.6, 155.6, 171.7; MS: [M]⁺ at *m/z* 632.11. Anal. Calcd for C₃₅H₃₀ClN₇O₃: C, 66.50; H, 4.78; N, 15.51. Found: C, 66.50; H, 4.76; N, 15.53%.

2-Methyl-5-methoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl)-3-(2-methoxyphenyl azo)pyrazolin-4-yl)indole, 4c: Yield 67% (Acetone); m.p. 248°C. IR (KBr): 1039 (C-O-C), 1293 (N-N), 1426 (N=N), 1590 (C=N), 1629 (C=C of aromatic ring), 1735 (C=O), 3352 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.43 (s, 3H, CH₃), 3.10 (t, 2H, *J* = 6.0 Hz, CH₂CH₂), 3.28 (q, 2H, *J* = 7.2 Hz, CH₂NH), 3.56 (s, 6H, 2 × OCH₃), 3.76 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 5.42 (brs, 1H, NHCH₂ exchangeable with D₂O), 5.70 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.87-7.89 (m, 16H, Ar-H), 8.93 (ss, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 15.9, 22.4, 34.7, 39.0, 46.9, 55.8, 67.5, 102.0, 103, 104.8, 111.5, 112.1, 112.2, 107.3, 120.9, 122.6, 123.3, 124.7, 125.7, 126.9, 127.2, 127.5, 129.2, 137, 150.2, 150.9, 154.0, 154.1, 154.9, 155.6, 159.6, 171.7; MS: [M]⁺ at *m/z* 627.69. Anal. Calcd for C₃₆H₃₃N₇O₄: C, 68.88; H, 5.30; N, 15.62. Found: C, 68.86; H, 5.31; N, 15.63%.

2-Methyl-5-ethoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl)-3-(phenylazo)pyrazolin-4-yl)indole, 4d: Yield 74% (Petroleum ether); m.p. 257°C.

IR (KBr): 1047 (C-O-C), 1290 (N-N), 1424 (N=N), 1594 (C=N), 1632 (C=C of aromatic ring), 1733 (C=O), 3338 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.47 (s, 3H, CH₃), 2.38 (t, 3H, *J* = 7.3 Hz, OCH₂CH₃), 3.16 (t, 2H, *J* = 6.0 Hz, CH₂CH₂), 3.26 (d, (q, 2H, *J* = 7.2 Hz, CH₂NH), 3.76 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 3.92 (q, 2H, *J* = 7.3 Hz, OCH₂CH₃), 5.46 (brs, 1H, NHCH₂ exchangeable with D₂O), 5.69 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.87-7.78 (m, 17H, Ar-H), 8.95 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 22.4, 34.7, 39.0, 46.9, 55.8, 67.5, 102.0, 103, 104.8, 107.3, 112.1, 112.2, 111.5, 120.9, 122.6, 123.3, 124.7, 125.7, 126.9, 127.2, 127.5, 129.2, 137, 150.2, 150.9, 154.0, 154.1, 154.9, 159.6, 155.6, 171.7; MS: [M]⁺ at *m/z* 611.69. Anal. Calcd for C₃₆H₃₃N₇O₃: C, 70.69; H, 5.44; N, 16.03. Found: C, 70.67; H, 5.45; N, 16.05%.

2-Methyl-5-ethoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl)-3-(2-chlorophenylazo) pyr-azolin-4-yl)indole, 4e: Yield 65% (Methanol); m.p. 260°C. IR (KBr): 759 (C-Cl), 1042 (C-O-C), 1292 (N-N), 1421 (N=N), 1590 (C=N), 1626 (C=C of aromatic ring), 1734 (C=O), 3356 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.43 (s, 3H, CH₃), 2.34 (t, 3H, *J* = 7.2 Hz, OCH₂CH₃), 3.12 (t, 2H, *J* = 6.0 Hz, CH₂CH₂), 3.23 (q, 2H, *J* = 7.2 Hz, CH₂NH), 2.85 (q, 2H, *J* = 7.3 Hz, OCH₂CH₃), 3.79 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 5.50 (brs, 1H, NHCH₂ exchangeable with D₂O); 5.67 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.77-7.88 (m, 16H, Ar-H), 8.98 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 22.4, 34.7, 39.0, 46.9, 55.8, 67.5, 102.0, 103, 104.8, 107.3, 111.5, 112.1, 112.2, 120.9, 123.3, 124.0, 124.7, 126.9, 127.1, 127.2, 127.3, 127.5, 128.1, 129.3, 137, 150.2, 151.1, 154.0, 154.1, 154.9, 155.6, 159.6, 171.7; MS: [M]⁺ at *m/z* 646.14. Anal. Calcd for C₃₆H₃₂ClN₇O₃: C, 66.92; H, 4.99; N, 15.17. Found: C, 66.94; H, 4.97; N, 15.19%.

2-Methyl-5-ethoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl)-3-(2-methoxyphenylazo) pyrazolin-4-yl)indole, 4f: Yield 67% (Methanol); m.p. 239°C. IR (KBr): 1035 (C-O-C), 1295 (N-N), 1428 (N=N), 1591 (C=N), 1625 (C=C of aromatic ring), 1723 (C=O), 3349 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.39 (t, 3H, *J* = 7.3 Hz, CH₂CH₃), 3.10 (t, 2H, *J* = 6.0 Hz, CH₂CH₂), 3.33 (q, 2H, *J* = 7.2 Hz, CH₂NH), 2.87 (q, 2H, *J* = 7.2 Hz, CH₂CH₃), 3.59 (s, 6H, 2 × OCH₃), 3.74 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 5.43 (brs, 1H, NHCH₂ exchangeable with D₂O), 5.69 (d,

1H, $J = 7.5$ Hz, CH of pyrazoline ring), 6.97-7.79 (m, 16H, Ar-H), 8.98 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 22.4, 34.7, 39.0, 46.9, 55.8, 67.5, 102.0, 103, 104.8, 107.3, 111.5, 112.1, 112.2, 114.8, 120.9, 121.5, 121.7, 122.8, 123.3, 123.6, 124.7, 126.9, 127.2, 127.5, 137, 150.2, 152.8, 154.0, 154.1, 154.9, 155.6, 159.6, 171.7; MS: [M]⁺ at m/z 641.72. Anal. Calcd for C₃₇H₃₅N₇O₄: C, 69.25; H, 5.50; N, 15.28. Found: C, 69.22; H, 5.52; N, 15.30%.

2-Ethyl-5-methoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl-3-(phenylazo) pyrazolin-4-yl)indole, 4g: Yield 70% (Methanol); m.p. 270°C. IR (KBr): 1039 (C-O-C), 1290 (N-N), 1428 (N=N), 1590 (C=N), 1629 (C=C of aromatic ring), 1733 (C=O), 3356 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.37 (t, 3H, $J = 7.0$ Hz, CH₂CH₃), 3.17 (t, 2H, $J = 6.0$ Hz, CH₂CH₂), 3.31 (q, 2H, $J = 7.2$ Hz, CH₂NH), 2.88 (q, 2H, $J = 7.2$ Hz, CH₂CH₃), 3.59 (s, 3H, OCH₃), 3.74 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 5.46 (brs, 1H, NHCH₂ exchangeable with D₂O), 5.69 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 6.97-7.79 (m, 17H, Ar-H), 8.98 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 14.8, 15.9, 34.7, 39.0, 46.9, 64.6, 67.5, 102.0, 103, 104.9, 107.3, 111.5, 117.1, 111.7, 120.9, 122.6, 123.3, 124.7, 125.7, 126.8, 126.9, 128.6, 129.2, 131.1, 124.7, 126.9, 150.2, 150.9, 153.4, 154.1, 154.9, 155.6, 159.6, 171.7; MS: [M]⁺ at m/z 611.69. Anal. Calcd for C₃₆H₃₃N₇O₃: C, 70.69; H, 5.44; N, 16.03. Found: C, 70.67; H, 5.45; N, 16.01%.

2-Ethyl-5-methoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl-3-(2-chlorophenylazo) pyrazolin-4-yl)indole, 4h: Yield 68% (Ethanol); m.p. 260°C. IR (KBr): 761 (C-Cl), 1040 (C-O-C), 1295 (N-N), 1420 (N=N), 1592 (C=N), 1626 (C=C of aromatic ring), 1720 (C=O), 3350 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.34 (t, 3H, $J = 7.0$ Hz, CH₂CH₃), 3.13 (t, 2H, $J = 6.0$ Hz, CH₂CH₂), 3.30 (q, 2H, $J = 7.2$ Hz, CH₂NH), 2.82 (q, 2H, $J = 7.2$ Hz, CH₂CH₃), 3.53 (s, 3H, OCH₃), 3.76 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 5.42 (brs, 1H, NHCH₂ exchangeable with D₂O), 5.62 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 6.87-7.89 (m, 16H, Ar-H), 8.96 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 14.8, 15.9, 34.7, 39.0, 46.9, 64.6, 67.5, 102.0, 103, 104.9, 107.3, 111.5, 111.7, 117.1, 120.9, 123.3, 124.0, 124.7, 126.8, 126.9, 127.1, 127.3, 128.1, 129.3, 131.1, 150.2, 151.1, 153.4, 154.9, 154.1, 155.6, 159.6, 171.7; MS: [M]⁺ at m/z 646.14. Anal. Calcd for C₃₆H₃₂ClN₇O₃: C, 66.92; H, 4.99; N, 15.17. Found: C, 66.94; H, 4.97; N, 15.19%.

2-Ethyl-5-methoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl-3-(2-methoxyphenyl azo) pyrazolin-4-yl)indole 4i: Yield 72% (Methanol); m.p. 268°C. IR (KBr): 1039 (C-O-C), 1294 (N-N), 1423 (N=N), 1592 (C=N), 1628 (C=C of aromatic ring), 1726 (C=O), 3347 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.37 (t, 3H, $J = 7.0$ Hz, CH₂CH₃), 3.10 (t, 2H, $J = 6.0$ Hz, CH₂CH₂), 3.27 (q, 2H, $J = 7.2$ Hz, CH₂NH), 2.86 (q, 2H, $J = 7.2$ Hz, CH₂CH₃), 3.59 (s, 6H, 2 × OCH₃), 3.74 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 5.45 (brs, 1H, NHCH₂ exchangeable with D₂O), 5.69 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 6.97-7.69 (m, 16H, Ar-H), 8.93 (s, 1H, NH of indole exchangeable with D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 14.8, 15.9, 34.7, 39.0, 46.9, 55.8, 64.6, 67.5, 102.0, 103, 104.9, 107.3, 111.5, 114.8, 111.7, 117.1, 120.9, 121.5, 121.7, 122.8, 123.3, 123.6, 124.7, 126.8, 126.9, 131.1, 150.2, 154.9, 152.8, 153.4, 154.1, 155.6, 159.6, 171.7; MS: [M]⁺ at m/z 641.72. Anal. Calcd for C₃₇H₃₅N₇O₄: C, 69.25; H, 5.50; N, 15.28; Found: C, 69.24; H, 5.48; N, 15.27%.

2-Ethyl-5-ethoxy - 3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl-3-(phenylazo) pyrazolin-4-yl) indole, 4j: Yield 74% (Acetone); m.p. 255°C. IR (KBr): 1039 (C-O-C), 1292 (N-N), 1421 (N=N), 3353 (NH), 1593 (C=N), 1625 (C=C of aromatic ring), 1724 (C=O), 3346 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.41 (t, 3H, $J = 7.3$ Hz OCH₂CH₃), 2.30 (t, 3H, $J = 7.3$ Hz, CH₂CH₃), 3.05 (t, 2H, $J = 6.0$ Hz, CH₂CH₂), 3.25 (q, 2H, $J = 7.2$ Hz, CH₂NH), 2.92 (q, 2H, $J = 7.2$ Hz, CH₂CH₃), 5.46 (brs, 1H, NHCH₂ exchangeable with D₂O), 3.95 (q, 2H, $J = 7.3$ Hz, OCH₂CH₃), 3.78 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 5.66 (d, 1H, $J = 7.5$ Hz, CH of pyrazoline ring), 6.69-7.69 (m, 17H, Ar-H), 8.90 (s, 1H, indole exchangeable With D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 14.8, 22.4, 34.7, 39.0, 46.9, 64.6, 67.5, 102.0, 103, 107.3, 104.9, 111.5, 111.7, 117.1, 120.9, 122.6, 123.3, 124.7, 125.7, 126.8, 126.9, 129.2, 137.0, 150.2, 150.9, 153.4, 154.1, 154.9, 155.6, 159.6, 171.7; MS: [M]⁺ at m/z 611.69. Anal. Calcd for C₃₇H₃₅N₇O₃: C, 70.69; H, 5.44; N, 16.03. Found: C, 70.68; H, 5.45; N, 16.05%.

2-Ethyl-5-ethoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl-3-(2-chlorophenyl azo) pyrazolin-4-yl)indole, 4k: Yield 63% (Methanol); m.p. 271°C. IR (KBr): 766 (C-Cl), 1036 (C-O-C), 1292 (N-N), 1426 (N=N), 1594 (C=N), 1627 (C=C of aromatic ring), 1722 (C=O, COCH₃), 3356 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 2.32 (t, 3H, $J = 7.0$ Hz, CH₂CH₃), 2.37 (t, 3H, $J = 7.3$ Hz OCH₂CH₃), 2.92 (q, 2H, $J = 7.2$

Table I — Antiparkinsonian activity of compounds **3a-l** and **4a-l**

Compd.	R	R'	R''	Oxotremorine induced tremors in mice (0.5 mg/kg)	Reserpine induced (5 mg/kg)		LD ₅₀ mg/kg i.p.
					Rigidity (%)	Hypokinesia (% counts)	
Control	-	-	-	3.0 ± 0	100	14.06	
L-Dopa	-	-	-	2.60 ± 0.26	80	30.39	
3a	CH ₃	OCH ₃	H	2.15 ± 0.28	80	53.80	1000
3b	CH ₃	OCH ₃	2-Cl	2.36 ± 0.21	40	67.10	1000
3c	CH ₃	OCH ₃	2-OCH ₃	2.39 ± 0.26	50	56.25	1000
3d	CH ₃	OC ₂ H ₅	H	2.17 ± 0.24	50	60.60	1000
3e	CH ₃	OC ₂ H ₅	2-Cl	2.19 ± 0.35	40	74.50	1000
3f	CH ₃	OC ₂ H ₅	2-OCH ₃	2.53 ± 0.15	60	64.10	1000
3g	C ₂ H ₅	OCH ₃	H	2.20 ± 0.27	80	49.80	1000
3h	C ₂ H ₅	OCH ₃	2-Cl	2.51 ± 0.26	30	70.10	1000
3i	C ₂ H ₅	OCH ₃	2-OCH ₃	2.28 ± 0.12	50	56.30	1000
3j	C ₂ H ₅	OC ₂ H ₅	H	2.23 ± 0.10	60	73.60	1000
3k	C ₂ H ₅	OC ₂ H ₅	2-Cl	2.49 ± 0.14	40	74.20	1000
3l	C ₂ H ₅	OC ₂ H ₅	2-OCH ₃	2.28 ± 0.26	50	73.70	1000
4a	CH ₃	OCH ₃	H	2.32 ± 0.28	70	54.06	1000
4b	CH ₃	OCH ₃	2-Cl	2.15 ± 0.25	30	70.39	1000
4c	CH ₃	OCH ₃	2-OCH ₃	2.26 ± 0.21	50	63.80	1000
4d	CH ₃	OC ₂ H ₅	H	2.39 ± 0.26	60	57.10	1000
4e	CH ₃	OC ₂ H ₅	2-Cl	2.21 ± 0.24	30	76.20	1000
4f	CH ₃	OC ₂ H ₅	2-OCH ₃	2.19 ± 0.35	30	79.60	1000
4g	C ₂ H ₅	OCH ₃	H	2.23 ± 0.10	40	64.50	1000
4h	C ₂ H ₅	OCH ₃	2-Cl	2.10 ± 0.27	10	90.10	1600
4i	C ₂ H ₅	OCH ₃	2-OCH ₃	2.31 ± 0.23	50	69.80	1000
4j	C ₂ H ₅	OC ₂ H ₅	H	2.26 ± 0.23	80	80.20	1000
4k	C ₂ H ₅	OC ₂ H ₅	2-Cl	2.38 ± 0.10	40	76.30	1000
4l	C ₂ H ₅	OC ₂ H ₅	2-OCH ₃	2.25 ± 0.20	50	73.60	1000

Hz, CH₂CH₃), 3.15 (t, 2H, *J* = 6.0 Hz, CH₂CH₂), 3.24 (q, 2H, *J* = 7.2 Hz, CH₂NH), 3.90 (q, 2H, *J* = 7.3 Hz, OCH₂CH₃), 3.78 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 5.52 (brs, 1H, NHCH₂ exchangeable with D₂O), 5.64 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.66-7.66 (m, 16H, Ar-H), 8.89 (s, 1H, NH indole exchangeable With D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 14.8, 22.4, 34.7, 39.0, 46.9, 64.6, 67.5, 102.0, 103, 104.9, 107.3, 111.5, 111.7, 117.1, 120.9, 123.3, 124.0, 124.7, 126.8, 126.9, 127.1, 127.3, 128.1, 129.3, 137.0, 150.2, 151.1, 153.4, 154.1, 154.9, 155.6, 159.6, 171.7; MS: [M]⁺ at *m/z* 660.16. Anal. Calcd for C₃₇H₃₄ClN₇O₃: C, 67.32; H, 5.19; N, 14.85. Found: C, 67.34; H, 5.21; N, 14.86%.

2-Ethyl-5-ethoxy-3-((2-benzofuran-2-yl)-1-(pyridinylamino)methyl-3-(2-methoxyphenyl azo)pyrazolin-4-yl)indole, 4l: Yield 66% (Petroleum ether); m.p. 262°C. IR (KBr): 1048 (C-O-C), 1290 (N-N), 1426 (N=N), 1595 (C=N), 1629 (C=C of aromatic ring), 1729 (C=O, COCH₃), 3362 cm⁻¹ (NH); ¹H NMR (CDCl₃): δ 1.62 (t, 3H, *J* = 7.0 Hz, CH₂CH₃), 2.36 (t, 3H, *J* = 7.3 Hz, OCH₂CH₃), 2.87 (q, 2H, *J* = 7.2 Hz, CH₂CH₃), 3.10 (t, 2H, *J* = 6.0 Hz, CH₂CH₂), 3.28

(q, 2H, *J* = 7.2 Hz, CH₂NH), 3.55 (s, 3H, OCH₃), 3.72 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 3.92 (q, 2H, *J* = 7.3 Hz, OCH₂CH₃), 5.57 (brs, 1H, NHCH₂ exchangeable with D₂O), 5.62 (d, 1H, *J* = 7.5 Hz, CH of pyrazoline ring), 6.79-7.99 (m, 16H, Ar-H), 8.90 (s, 1H, indole exchangeable With D₂O); ¹³C NMR (400 MHz, CDCl₃): δ 13.7, 14.8, 22.4, 34.7, 39.0, 46.9, 55.8, 64.6, 67.5, 102.0, 103, 104.9, 107.3, 111.5, 111.7, 117.1, 114.8, 120.9, 121.5, 121.7, 122.8, 123.3, 123.6, 124.7, 126.8, 126.9, 137.0, 150.2, 152.8, 153.4, 154.1, 154.9, 155.6, 159.6, 171.7. MS: [M]⁺ at *m/z* 655.74. Anal. Calcd for C₃₈H₃₇N₇O₄: C, 69.60; H, 5.69; N, 14.95. Found: C, 69.58; H, 5.68; N, 14.93%.

Conclusion

The antiparkinsonian activities of the synthesized compounds were determined by *in vivo test*. The experimental data of all the compounds of this series have been reported in **Table Ia**,

Anti-tremor activity

Among all the compounds, compounds **3b**, **3c**, **3k**, **4a**, **4d**, and **4k** showed moderate antitremor activity.

Furthermore, compounds **3g**, **3j**, **4c**, **4e**, **4g**, **4j** and **4l** exhibited good antitremor activity. The compounds **3a**, **3d**, **3e**, **4b** and **4f** showed interesting response against oxotremorine induced tremors. Moreover, compound **4h** (having 2-chlorophenyl moiety) have shown maximum anti-tremor activity (2.10 ± 0.10 score).

Antirigidity activity

Compounds **4b**, **4e** and **4f** significantly antagonized the reserpine induced rigidity. Furthermore, compounds **3b-3e**, **3i**, **3k**, **3l**, **4c**, **4g**, **4i**, **4k** and **4l** showed good activity *i.e.* 50-60%. The compound **4h** has shown 90% response against reserpine induced rigidity.

Antihypokinetic Activity

The compounds **3a**, **3c**, **3i**, **4a** and **4d** showed moderate antihypokinetic activity, while compounds **3b**, **3d**, **4c**, **4g** and **4i** exhibited good antihypokinetic activity. The compounds **3e**, **3h**, **3j**, **3k**, **3l**, **4b**, **4e**, **4f**, **4j**, **4k**, and **4l** showed interesting activity. Moreover, compounds **4h** showed most potent (*i.e.* 90.10%) antihypokinetic activity.

Acute Toxicity

The newly synthesized compounds were also tested for lethal dose LD₅₀ and were found to exhibit a high value of LD₅₀ *i.e.* more than 1000 mg/kg *i.p.* except compound **4h** which exhibited LD₅₀ of more than 1600 mg/kg *i.p.* (maximum dose tested). Therefore, all these compounds have shown high value of LD₅₀ thus indicating good safety margin.

Acknowledgement

The authors are thankful to the Director SAIF Punjab University, Chandigarh and CDRI Lucknow,

India for spectral and analysis of newly synthesized compounds. One of the authors, Hemlata Kaur (J.R.F.) is also thankful to UGC New Delhi, India for the award of Rajiv Gandhi National Junior Research Fellowship and financial support for this work.

References

- 1 Alexi T, Borlogan C V, Faull R L M, Williams C E, Clark R G, Gluckman P D & Hughes P E, *Progr Neurobiol*, 60, **2000**, 409.
- 2 Sanze E, Romera M, Bellick L, Marco J L & Unzeta M, *Med Sci Monit*, 10, **2004**, 477.
- 3 Kumar A, Agarwal J C, Nath C, Gurtu S, Sinha J N, Bhargava K P & Shanker K, *J Heterocycl Chem*, 18, **1981**, 1269.
- 4 Kumar P, Nath C, Bhargava K P & Shanker K, *Curr Sci*, 52, **1983**, 795.
- 5 Archana, Rani P, Bajaj K, Srivastava V K, Chandra R & Kumar A, *Arzneim Forsch/Drug Research*, 53, **2003**, 301.
- 6 Bajaj K, Srivastava V K, Lata S, Chandra R & Kumar A, *Indian J Chem*, 42B, **2003**, 723.
- 7 Masaguer C F, Ravina E, Isabel L & Fontenlo J A, *Bio Med Chem Lett*, 7, **1997**, 913.
- 8 Abdul-Latif N A, Sabry N M, Mohamed M & Abdulla M M, *Monatsh Fur Chem* 138, **2007**, 715.
- 9 Kelley J L, Koble C S, Davis R G, Mclean E W, Soroko F E & Cooper B R, *J Med Chem*, 38, **1995**, 4131.
- 10 Amr A E G E, Maigali S S & Abdulla M M, *Monatsh Fur Chem*, 139, **2008**, 1409.
- 11 Amr A E G E, Hegab M I, Ibrahiem A A & Abdulla M M, *Monatsh Fur Chem*, 134, **2003**, 395.
- 12 Hirokawa Y, Fujiwara I, Suzuki K, Harada H, Yoshikawa T, Yoshida N & Kato S, *J Med Chem*, 46, **2003**, 702.
- 13 Kelly J L, Koble C S, Davis R G, Mclean E W, Soroko F E & Cooper B R, *J Med Chem*, 38, **1995**, 4131.
- 14 Coward D M & Dogges N S, *Psycho Pharmacol*, 52, **1997**, 165.
- 15 Goldstein J M, Barnett A & Malick J B, *Eur J Pharmacol*, 33, **1975**, 183.
- 16 Morpugo C, *Arch Int Pharmacodyn Ther*, 8, **1962**, 46.
- 17 Smith Q E, *Pharmacological screening tests progress in medicinal Chemistry* (Butterworths, London) 1, **1960**, 1.